Altria Group heads into its July 30 Q2 earnings report with options traders showing their most defensive posture in months.
Options positioning is the clearest signal of investor unease. The put/call ratio has climbed to 1.13, nearly two standard deviations above its 20-day average of 0.81 — a level only exceeded by the 52-week high of 1.45. That shift is recent and sharp: the PCR ran below 0.70 as recently as early July before reversing hard. Investors are paying notably more for downside protection than they were just three weeks ago.
The borrow market tells a different story — one of almost complete indifference from short sellers. Availability is exceptionally loose at over 3,000% of short interest, meaning roughly thirty shares are available to borrow for every one currently lent out. Short interest itself has eased 16% over the past month to just 2.9% of the free float. Cost to borrow has ticked up about 31% over the past week but remains trivially low at 0.47%. The ORTEX short score of 39 sits comfortably below any threshold that would flag squeeze or accumulation pressure. There is no meaningful short thesis building here — the options hedging is a standalone signal, not confirmation of a broader bearish setup.
The analyst community is split but tilting cautiously bullish. UBS raised its target to $79 earlier this month — the most recent move from a major firm, and a notable endorsement given the stock trades near $73. Barclays sits at the other end, maintaining an Underweight with a $64 target, reflecting the bear case: cigarette consumption below 15% of adult users and declining, with the On! oral nicotine brand not yet large enough to fill the gap. Bulls counter that Marlboro's 42% domestic market share generates durable cash flows, and the On! brand's 8.8% retail share is expanding at a solid clip. The consensus is a hold, with 8 analysts there and no clear direction of travel beyond target-price inflation across the board.
The Q1 print in April delivered a +9.3% single-day move — the largest reaction in recent memory — before fading to a more modest +1.2% over the following five days. That kind of asymmetric day-one pop followed by mean reversion is worth noting as context for how the market has priced in a strong number only to reassess. The July 30 report will test whether Altria's pricing power is holding against accelerating volume declines, and whether the smoke-free portfolio has grown enough to matter to near-term earnings.
See the live data behind this article on ORTEX.
Open MO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
